Sofinnova Investments, Inc. — 13F Holdings & Portfolio
CIK 1631134 · latest 13F-HR filed 2026-08-14
Sofinnova Investments, Inc. manages $1.93B in 13F-reported U.S. long-equity assets across 57 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are NTRA (21.76%), VERA (6.20%), GMAB (5.74%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 11 new positions and exited 19; 24 existing positions rose in reported value and 14 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
| Name | Title / Status | Ownership | Type |
|---|
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- Natera Inc$110.8M +35.7%
- Genmab A/S$90.9M +450.6%
- Arrivent BioPharma Inc$19.8M +50.6%
- Rapport Therapeutics Inc$19.8M +33.2%
- Anaptysbio Inc$19.5M +142.0%
Top Trims
- Bristol-Myers Squibb Co-$70.1M -58.1%
- United Therapeutics Corp Del-$53.5M -56.3%
- Cogent Biosciences Inc-$41.3M -50.8%
- Insmed Inc-$39.7M -70.2%
- Alcon AG-$37.8M -68.8%
New Positions
- Seaport Therapeutics Inc$77.4M
- Gilead Sciences Inc$43.3M
- Nurix Therapeutics Inc$12.7M
- Design Therapeutics Inc$12.5M
- First Tracks Biotherapeutics$11.4M
Exited Positions
- AstraZeneca PLC$89.9M
- Biogen Inc$42.1M
- Celcuity Inc$41.8M
- BridgeBio Pharma Inc$30.4M
- Dexcom Inc$24.7M
Sofinnova Investments, Inc. Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | Natera Inc | NTRA | 632307104 | $420.8M | 21.76% | 1,550,280 | SH |
| 2 | Vera Therapeutics Inc | VERA | 92337R101 | $119.9M | 6.20% | 2,793,987 | SH |
| 3 | Genmab A/S | GMAB | 372303206 | $111.1M | 5.74% | 4,045,215 | SH |
| 4 | Jazz Pharmaceuticals PLC | JAZZ | G50871105 | $88.0M | 4.55% | 365,341 | SH |
| 5 | Rapport Therapeutics Inc | RAPP | 75383L102 | $79.4M | 4.10% | 1,904,408 | SH |
| 6 | Seaport Therapeutics Inc | SPTX | 81221K108 | $77.4M | 4.00% | 3,564,871 | SH |
| 7 | Arrivent BioPharma Inc | AVBP | 04272N102 | $58.9M | 3.05% | 1,696,752 | SH |
| 8 | Ultragenyx Pharmaceutical In | RARE | 90400D108 | $57.3M | 2.96% | 1,717,505 | SH |
| 9 | BioAge Labs Inc | BIOA | 09077V100 | $56.2M | 2.91% | 2,293,788 | SH |
| 10 | Bristol-Myers Squibb Co | BMY | 110122108 | $50.5M | 2.61% | 876,970 | SH |
| 11 | Supernus Pharmaceuticals | SUPN | 868459108 | $48.2M | 2.49% | 1,036,328 | SH |
| 12 | Rhythm Pharmaceuticals Inc | RYTM | 76243J105 | $45.3M | 2.34% | 408,027 | SH |
| 13 | Gilead Sciences Inc | GILD | 375558103 | $43.3M | 2.24% | 343,100 | SH |
| 14 | United Therapeutics Corp Del | UTHR | 91307C102 | $41.4M | 2.14% | 76,489 | SH |
| 15 | Cogent Biosciences Inc | COGT | 19240Q201 | $40.1M | 2.07% | 1,035,148 | SH |
| 16 | Axsome Therapeutics Inc. | AXSM | 05464T104 | $39.3M | 2.03% | 160,429 | SH |
| 17 | Immatics N.V | IMTX | N44445109 | $37.2M | 1.92% | 3,669,346 | SH |
| 18 | Dyne Therapeutics Inc | DYN | 26818M108 | $36.8M | 1.90% | 1,658,384 | SH |
| 19 | Immunome Inc | IMNM | 45257U108 | $36.5M | 1.88% | 1,720,316 | SH |
| 20 | IDEAYA Biosciences Inc | IDYA | 45166A102 | $34.5M | 1.78% | 925,119 | SH |
| 21 | Anaptysbio Inc | ANAB | 032724106 | $33.3M | 1.72% | 493,536 | SH |
| 22 | Nektar Therapeutics | NKTR | 640268306 | $32.9M | 1.70% | 471,763 | SH |
| 23 | Pharvaris N V | PHVS | N69605108 | $30.5M | 1.58% | 881,299 | SH |
| 24 | Arcus Biosciences Inc | RCUS | 03969F109 | $29.2M | 1.51% | 945,690 | SH |
| 25 | Inhibrx Biosciences Inc | INBX | 45720N103 | $28.7M | 1.48% | 303,103 | SH |
| 26 | BioMarin Pharmaceutical Inc | BMRN | 09061G101 | $20.5M | 1.06% | 358,568 | SH |
| 27 | Veradermics Inc | MANE | 922967104 | $18.3M | 0.95% | 148,993 | SH |
| 28 | Alcon AG | ALC | H01301128 | $17.2M | 0.89% | 255,824 | SH |
| 29 | Insmed Inc | INSM | 457669307 | $16.9M | 0.87% | 158,398 | SH |
| 30 | Ultragenyx Pharmaceutical In Call | RARE | 90400D108 | $16.7M | 0.86% | 500,000 | SH |
| 31 | Intuitive Surgical Inc Call | ISRG | 46120E602 | $15.9M | 0.82% | 40,000 | SH |
| 32 | Globus Med Inc Call | GMED | 379577208 | $15.8M | 0.82% | 200,000 | SH |
| 33 | Edgewise Therapeutics Inc | EWTX | 28036F105 | $15.5M | 0.80% | 380,923 | SH |
| 34 | Exelixis Inc Put | EXEL | 30161Q104 | $13.8M | 0.72% | 254,200 | SH |
| 35 | Nurix Therapeutics Inc | NRIX | 67080M103 | $12.7M | 0.66% | 524,098 | SH |
| 36 | Design Therapeutics Inc | DSGN | 25056L103 | $12.5M | 0.65% | 865,135 | SH |
| 37 | Definium Therapeutics Inc | DFTX | 24477V105 | $12.0M | 0.62% | 255,903 | SH |
| 38 | First Tracks Biotherapeutics | TRAX | 337185102 | $11.4M | 0.59% | 565,199 | SH |
| 39 | Abbott Laboratories | ABT | 002824100 | $11.2M | 0.58% | 122,998 | SH |
| 40 | Disc Medicine Inc | IRON | 254604101 | $10.7M | 0.55% | 146,239 | SH |
| 41 | Tenax Therapeutics Inc | TENX | 88032L605 | $7.3M | 0.38% | 500,039 | SH |
| 42 | Sionna Therapeutics Inc | SION | 829401108 | $6.4M | 0.33% | 144,432 | SH |
| 43 | Absci Corporation | ABSI | 00091E109 | $3.9M | 0.20% | 337,400 | SH |
| 44 | Mirum Pharmaceuticals Inc | MIRM | 604749101 | $3.2M | 0.17% | 27,591 | SH |
| 45 | Jade Biosciences Inc | JBIO | 008064206 | $2.4M | 0.12% | 107,391 | SH |
| 46 | Savara Inc | SVRA | 805111101 | $2.2M | 0.12% | 364,763 | SH |
| 47 | Praxis Precision Medicines I | PRAX | 74006W207 | $2.2M | 0.11% | 6,440 | SH |
| 48 | Septerna Inc | SEPN | 81734D104 | $1.6M | 0.08% | 47,506 | SH |
| 49 | Onkure Therapeutics Inc | OKUR | 68277Q105 | $1.5M | 0.08% | 321,692 | SH |
| 50 | Sagimet Biosciences Inc | SGMT | 786700104 | $1.3M | 0.07% | 166,667 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $1.93B | 57 | 0001104659-26-096982 |
| 2026-03-31 | 2026-05-15 | $2.63B | 75 | 0001104659-26-062256 |
| 2025-12-31 | 2026-02-13 | $2.32B | 60 | 0001104659-26-015127 |
| 2025-09-30 | 2025-11-14 | $1.83B | 62 | 0001104659-25-111551 |
BUILDING 3-SUITE 150
Menlo Park, CA 94025